New leukemia agent paves way for transplants

A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-ar...

Full description

Saved in:
Bibliographic Details
Published in:Drug Topics 2005-12, Vol.149 (23), p.20
Main Author: Kelly Dowhower Karpa
Format: Magazinearticle
Language:English
Subjects:
Drug therapy
Leukemia
Lymphoma
Medical treatment
Pharmaceuticals
Stem cells
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new treatment option for treating T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) is on the horizon. In 2006, GlaxoSmithKline will begin marketing the recently approved nelarabine (Arranon), a water-soluble pro-drug of the cytotoxic deoxyguanosine analog 9-beta-D-arabinofuranosylguanine (ara-G). Acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells, affects children more often than adults. ALL accounts for 23% of all cancer diagnoses in children under 15 years of age. Each year, 2,400 children and 1,200 adults are diagnosed with ALL in the United States. There are several forms of ALL. The T-cell immunophenotype (T-ALL) represents a minority of the overall ALL population but has a particularly poor prognosis.
ISSN:0012-6616
1937-8157